×
0 0 0 0 0.00220669363736661 0 0.000504387117112403 0
Stockreport

Amgen's SCLC drug gets orphan status [Seeking Alpha]

Amgen, Inc (AMGN)  More Company Research Source: Seeking Alpha
Last amgen, inc earnings: 1/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
PDF The FDA grants orphan drug designation to Amgen's (NASDAQ: AMGN ) treatment for small cell lung cancer. The generic name is bispecific T-cell engager antibody consisting of 2 single chain variable fragment binding domains specific for antigen Delta-like protein 3 (DLL3) and for TCR-associated complex CD3. The generic description could refer to AMG 757. Amgen shares are   to $188.26. Click to subscribe to real-time analytics on AMGN Now read: Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund » Subscribe for full text news in your inbox [Read more]

IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
Opt-in for
AMGN alerts

from News Quantified
Opt-in for
AMGN alerts

from News Quantified